Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: telaglenastat | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 23 Parkinson's papers of 7,060 | 0.58 |
| pathways Reactome | 3 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 7277
Sealed predictions
- GLS in dopamine neurons, braak+0.66 (p 0.053) → -0.32 (p 0.400)receipt 7284
Swarm cases
receipt 7284: GLS in dopamine neurons, braak
- power
- full sample +0.23 (p 0.360, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.328, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.25 (p 0.310, n 18). could be the mix.
- skeptic
- leave-one-out range +0.15 to +0.38, sign flips 0; without severely affected donors +0.23 (p 0.360, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GLS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts